Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Germany
Clinical trial register · Germany

Clinical Trials in Germany

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 28 Dresden 19 Cologne 16 Hanover 10 Bonn 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Novartis Pharmaceuticals142 Hoffmann-La Roche99 Merck Sharp & Dohme LLC98 Eli Lilly and Company98 Charite University, Berlin, Germany95 Janssen Research & Development, LLC90 University Hospital Tuebingen87 AbbVie79 Universitätsklinikum Hamburg-Eppendorf78 Bristol-Myers Squibb67 Sanofi65 Boehringer Ingelheim61 Pfizer56 University Hospital Heidelberg52 Novo Nordisk A/S51 Amgen49 GlaxoSmithKline49 University of Erlangen-Nürnberg Medical School47 Technical University of Munich47 Heinrich-Heine University, Duesseldorf45 Technische Universität Dresden44 Bayer32 Takeda31 University of Ulm29 Show all 1399 Clear sponsor filter
Site location
Berlin28 Dresden19 Cologne16 Hanover10 Bonn10 Heidelberg10 Essen9 Hamburg9 Frankfurt9 Tübingen8 München8 Erlangen7 Mainz7 Freiburg im Breisgau7 Mannheim6 Aachen6 Leipzig5 Würzburg5 Bochum5 Bamberg4 Giessen4 Gauting3 Großhansdorf3 Biberach3 Bad Homburg3 Show all 64
All 64 locations
Target enrolment
to

Trials in this register

61 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Boehringer Ingelheim
Phase 3
68
Dresden, Frankfurt, Würzburg
2027-03-04
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2027-01-11
Not yet open
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-12-14
Not yet open
Boehringer Ingelheim
Phase 3
600
Bad Homburg, Erlangen, Freiburg im Breisgau, Leipzig, Mainz
2026-11-18
Not yet open
Boehringer Ingelheim
Phase 2
70
Aachen, Berlin, Donaustauf, Solingen, Stralstund
2026-11-13
Recruiting
Boehringer Ingelheim
Phase 1
40
Berlin
2026-11-03
Recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Mainz, Stuttgart
2026-11-03
Recruiting
Boehringer Ingelheim
Phase 1
36
Biberach
2026-10-14
Recruiting
Boehringer Ingelheim
Phase 1/2
55
Dresden, Essen, Tübingen
2026-10-01
Recruiting
Boehringer Ingelheim
Phase 1
137
Dresden, München
2026-09-21
Recruiting
Boehringer Ingelheim
Phase 3
466
Berlin, Bonn, Essen, Hanover, Heidelberg, München, Stuttgart
2026-09-17
Recruiting
Boehringer Ingelheim
Phase 1
20
Berlin
2026-09-10
Recruiting
Boehringer Ingelheim
Phase 1
56
Biberach
2026-09-09
Active, closed
Boehringer Ingelheim
Phase 1
44
Mannheim
2026-09-02
Active, closed
Boehringer Ingelheim
Phase 1
10
Biberach
2026-09-01
Recruiting
Boehringer Ingelheim
Phase 1
70
Mannheim
2026-09-01
Active, closed
Boehringer Ingelheim
Phase 1
56
Mannheim
2026-08-20
Recruiting
Boehringer Ingelheim
Phase 3
448
Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
35
Berlin, Hamburg, Hanover
2026-07-21
Recruiting
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
Boehringer Ingelheim
Phase 2
60
Cologne, Heidelberg
2026-06-04
Recruiting
Boehringer Ingelheim
Phase 2
405
Minden, München
2026-04-20
Recruiting
Boehringer Ingelheim
Phase 3
670
Aachen, Berlin, Berlin-Spandau, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Gauting
2026-04-13
Recruiting
Boehringer Ingelheim
Phase 2
132
Berlin, Cologne, Hamburg, Hanover, Mainz, München
2026-03-23
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
München, Würzburg
2026-02-27
Recruiting
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Essen, Hanover, Immenhausen, Solingen
2026-02-10
Recruiting
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Active, closed
Boehringer Ingelheim
Phase 3
135
Cologne, Hamburg, Heidelberg, Tübingen
2025-12-09
Active, closed
Boehringer Ingelheim
Phase 2
81
Essen, Hanover
2025-11-13
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Active, closed
Boehringer Ingelheim
Phase 1
16
Dresden, Hanover, Tübingen
2025-07-29
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bremen, Bruchsal, Coburg
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 2
300
Dresden, Düsseldorf, Leipzig, Mannheim, Münster
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bad Friedrichshall, Bad Homburg, Bamberg, Berlin, Bonn, Bünde, Coburg, Dresden
2025-05-20
Active, closed
Boehringer Ingelheim
Phase 1
91
Braunschweig, Jena, Leipzig, Ulm
2025-05-14
Recruiting
Boehringer Ingelheim
Phase 1
172
Berlin
2025-01-23
Active, closed
Boehringer Ingelheim
Phase 2
90
Berlin, Tübingen
2024-12-30
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
Berlin, Giessen, Hamburg, Leipzig, Mannheim, München
2024-10-11
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Ahrensburg, Bamberg, Berlin, Bonn, Coswig, Essen, Hamburg, Hanover
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Aachen, Bad Kreuznach, Bad Nenndorf, Bad Oeynhausen, Berlin, Bonn, Braunschweig, Cloppenburg
2024-08-30
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Aachen, Bad Friedrichshall, Berlin, Bonn, Dessau, Dresden, Erfurt, Frankfurt
2024-06-17
Recruiting
Boehringer Ingelheim
Phase 2
175
Bonn, Mainz, Neubrandenburg, Tübingen, Ulm
2024-05-15
Active, closed
Boehringer Ingelheim
Phase 1
69
Dresden, Erlangen, Heidelberg, Mainz, Würzburg
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 1
46
Giessen
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Boehringer Ingelheim
Phase 1
20
Frankfurt, München, Tübingen
2024-01-30
Active, closed
Boehringer Ingelheim
Phase 1
65
München, Tübingen
2024-01-22
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Berlin, Dresden, Erlangen, Gauting, Großhansdorf, Mainz
2023-10-13
Active, closed
Boehringer Ingelheim
Phase 2
268
Berlin, Essen, Frankfurt, Großhansdorf, Hanover, Immenhausen, Jena, Konstanz
2023-09-08
Active, closed
Boehringer Ingelheim
Phase 1
45
Dresden, Frankfurt
2023-06-27
Active, closed
Boehringer Ingelheim
Phase 1
59
Hamburg
2023-05-11
Active, closed
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
NCT05708599Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
Not applicable
102
Kiel
2023-03-01
Active, closed
Boehringer Ingelheim
Phase 1
151
Freiburg im Breisgau, Halle, Stuttgart
2021-10-18
Recruiting
Boehringer Ingelheim
Phase 1
554
Augsburg, Cologne, Dresden, Giessen, Oldenburg
2021-07-02
Active, closed
Boehringer Ingelheim
Phase 1
306
Cologne, Dresden, Würzburg
2020-07-29
Active, closed
Boehringer Ingelheim
Phase 1
71
Cologne, Frankfurt am Main
2019-11-04
Rows per page Showing 1–61 of 61
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-germany

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 61 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Germany?

34 of the 61 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 5 have not yet opened recruitment, 22 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 61 studies
PhaseStudiesRecruitingShare
Phase 1231037.7%
Phase 3231437.7%
Phase 211718%
Phase 1/2334.9%
Not applicable101.6%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Boehringer Ingelheim6134

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Healthy (8) Neuroendocrine Neoplasms (3) Obesity (3) Interstitial Lung Diseases (3) Bronchiectasis (3) Idiopathic Pulmonary Fibrosis (3) Solid Tumours (3) Small Cell Lung Carcinoma (SCLC) (3) Pancreatic Ductal Adenocarcinoma (2) Heart Failure (2) Lung Cancer, Non-squamous, Non-small Cell (2) Small Cell Lung Carcinoma (1) Extra-pulmonary Neuroendocrine Carcinoma (1) Non-Small-Cell Lung Carcinoma (1) Colorectal Cancer (1)
→

Browse trials by site location

Berlin (28) Dresden (19) Cologne (16) Hanover (10) Bonn (10) Heidelberg (10) Essen (9) Hamburg (9) Frankfurt (9) Tübingen (8) München (8) Erlangen (7) Mainz (7) Freiburg im Breisgau (7) Mannheim (6)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.